Health and Healthcare
FDA's First Stent Approval Since 2004 (MDT, JNJ, BSX, ABT)
Published:
Medtronic, Inc. (NYSE: MDT) has just announced that it has received formal approval from the FDA to market its Endeavor Zotarolimus-Eluting Coronary Stent System for the treatment of coronary artery disease.
This had been under study for some time and had been used in more than 4,100 patients that had been followed-up for up to four years. Medtronic noted that this affects an estimated 13 million people in the United States and is the country’s leading cause of death. Medtronic will begin marketing of these stents immediately and said it EXPECTS TO SHIP 100,000 units to hospitals in the U.S. over just the next 30 days.
Boston Scientific (NYSE: BSX) and Johnson & Johnson (NYSE: JNJ) are competitors in this stent market, although stents have been under more scrutiny than in say 2003 to 2006. Abbott (NYSE: ABT) is still waiting on a yeah or nay out of the FDA on its new stent.
Jon C. Ogg
February 1, 2008
Want to Retire Early? Start Here (Sponsor)
Want retirement to come a few years earlier than you’d planned? Or are you ready to retire now, but want an extra set of eyes on your finances?
Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Have questions about retirement or personal finance? Email us at [email protected]!
By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on a673b.bigscoots-temp.com.
By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
